PROGRAM OVERVIEW
The goal of this activity is to educate health care professionals about current issues related to type 2 diabetes. This education will provide an overview and differentiation of currently available GLP1-RAs to manage this disease, including mechanism of action, dosing optimization and administration, glycemic and extra-glycemic effects, safety and tolerability concerns, and early place in therapy according to treatment guidelines.
LEARNING OBJECTIVES
Through content-based questions, reflection statements, and clinical case scenarios, learners will apply the information and strategies provided in this education to demonstrate improved confidence and abilities to:
•Differentiate available GLP-1 RAs based on therapy characteristics
•Utilize patient preferences and available treatment guidelines to select optimal GLP-1 RA for patients withT2D
•Implement strategies to manage potential side effects of GLP-1 RAs in the management ofT2D
FACULTY
Jay Shubrook, DO
Professor, Primary Care Department, College of Osteopathic Medicine
Touro University
Vallejo, CA
Leslie Goldstein, PharmD
Associate Professor of Pharmacology
New York Institute of Technology
New York, NY
INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the pretest, completing the activity, and completing the posttest and evaluation form. A score of at least 66% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.
Credit fulfillment
•If you are requesting AMA credits, AAFP credits, ANCC credits, AAPA credits, or a certificate of participation, your certificate will be available for download.
•If you are requesting AOA credit, ACOFP will submit your credit electronically within 90 days of completing the activity.
Accreditation Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of ACOFP, The France Foundation and the California Academy of Family Physicians. ACOFP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.
ACOFP is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designations
ACOFP designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. ACOFP designates this enduring activity for a maximum of 1.0 AOA Category 1-A credits and will report continuing medical education (CME) credits commensurate with the physician’s participation in this program.
DISCLOSURE POLICY
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, The France Foundation (TFF), The American College of Osteopathic Family Physicians (ACOFP), and The California Academy of Family Physicians (CAFP) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. TFF, ACOFP, and CAFP resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ACOFP, and CAFP seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ACOFP, and CAFP are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
| Name of Individual | Role in Activity | Name of Commercial Interest(s) | Nature of Relationship(s) | Mechanism(s) implemented to resolve conflict of interest |
| Emily Peck | TFF Staff | No relevant financial disclosures | NA | NA |
| Jay Shubrook, DO | Planning Committee Member, Faculty | 1. Abbott, Bayer, Novo Nordisk 2. AstraZeneca, Eli Lilly, Novo Nordisk |
1. Non-CE Consulting 2. Advisory board |
The following financial relationship has been mitigated by: •AstraZeneca ended prior to August 2023 All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee Member |
| Jerri L. Davis, CHCP |
CAFP Staff | No relevant financial disclosures | NA | NA |
| Laurie Isenberg | CAFP Staff | No relevant financial disclosures | NA | NA |
| Leslie Goldstein, PharmD | Planning Committee Member, Faculty | No relevant financial disclosures | NA | NA |
| Lyndsey Aspaas, CHCP |
ACOFP Staff | No relevant financial disclosures | NA | NA |
| Margaret Das, PhD |
TFF Content Reviewer | No relevant financial disclosures | NA | NA |
| Paige Zelinksy, MSc |
ACOFP Staff | No relevant financial disclosures | NA | NA |
| Stephen Legault, MSW, CAE | ACOFP Staff | No relevant financial disclosures | NA | NA |
Disclosure of Unlabeled Use:
TFF, ACOFP, and CAFP require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ACOFP, and CAFP do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an independent medical educational grant from Novo Nordisk.
Disclaimer
TFF, ACOFP, and CAFP present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ACOFP, CAFP and the commercial supporter(s) assume no liability for the information herein.